<?xml version="1.0" encoding="UTF-8"?>
<mods xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.loc.gov/mods/v3" version="3.1" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
  <titleInfo>
    <title>Determination of rifampicin in human plasma by reversed-phase liquid chromatography</title>
  </titleInfo>
  <name type="personal">
    <namePart>Santiago, Maria Lourdes C.</namePart>
  </name>
  <name type="personal">
    <namePart>Gonzales, Therese Irynne R.</namePart>
  </name>
  <name type="personal">
    <namePart>Sarau, Josephine K.</namePart>
  </name>
  <name type="personal">
    <namePart>Abejo, Vivianne O.</namePart>
  </name>
  <typeOfResource>text</typeOfResource>
  <originInfo>
    <issuance>monographic</issuance>
  </originInfo>
  <language>
    <languageTerm authority="iso639-2b" type="code">eng</languageTerm>
  </language>
  <physicalDescription>
    <form authority="marcform">print</form>
  </physicalDescription>
  <abstract>A simple, specific and sensitive high pressure liquid chromatographic method for the determination of rifampicin in human plasma of Filipino male and female healthy volunteers was developed and validated
This method utilizes a direct precipitation separation technique and ultraviolet detection monitored at 337 nm. Dipyridamole is used as the internal standard. Rifampicin and the internal standard were separated using a Bakerbond narrow pore octyl (C8, 5um, 120 A, 4.6 x 250 nm) reversed-phase column with 10 mM phosphate buffer (pH 5.2), acetonitrile, and tetrahydrofuran (65:35:10) as the mobile phase. The retention time was 7.7 minutes for rifampicin and 14.5 minutes for dipyridamole. Results showed a linear response in the concentraion range of 0.5 to 20 mg/L (r=0.99925). The limit of quantitation is 0.5 mg/L. Both intraday and interday accuracy and precision data showed good reproducibility.
The precision, accuracy, linearity, specificity, and sensitivity of the method were well-within the range of clinical utility and meet the requirements for bioavailability, bioequivalence, and pharmacokinetic studies.(Author)</abstract>
  <note type="statement of responsibility">Maria Lourdes C. Santiago [and three others]</note>
  <note>BFAD  Laboratory Information Bulletin, 1997  3 (1) pages 30-35</note>
  <subject authority="mesh">
    <topic>Rifampin</topic>
  </subject>
  <subject authority="mesh">
    <topic>Plasma</topic>
  </subject>
  <recordInfo>
    <recordCreationDate encoding="marc">210325</recordCreationDate>
    <recordChangeDate encoding="iso8601">20210325164301.0</recordChangeDate>
    <recordIdentifier source="DOH">D0001J000334</recordIdentifier>
  </recordInfo>
</mods>
